Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328103238> ?p ?o ?g. }
- W4328103238 endingPage "216140" @default.
- W4328103238 startingPage "216140" @default.
- W4328103238 abstract "Met proto-oncogene exon 14 skipping (METex14) mutations are targetable driver genes in approximately 3% of non-small-cell lung cancers (NSCLCs). Ensartinib, a type Ia MET inhibitor, is a multi-kinase inhibitor that has been approved for ALK-positive NSCLCs. Ensartinib was administered for compassionate use (cohort 1) and in a phase II clinical trial (cohort 2) to patients with METex14 mutant NSCLCs, with ORR as a primary endpoint. Molecular simulation was conducted to evaluate ensartinib c-MET interaction, and cell lines, patient-derived organoids (PDOs), and xenograft models were used to test the effectiveness of ensartinib. Among 29 evaluable patients, the ORR and DCR of ensartinib were 67% and 94% in cohort 1, and 73% and 91% in cohort 2. The median DoR was 6.8 months and median PFS was 6.1 months in the total population. Rash was the most common drug-related adverse event, and peripheral edema of any grade was reported in only 9% patients. Molecular simulations indicated favorable binding of ensartinib to c-MET. The kinase assay demonstrated an IC50 of 7.9 nM of ensartinib against METex14 protein. In vitro, Hs746T (METex14 mutation) and EBC-1 (MET amplification) cells were sensitive to ensartinib, with IC50 values of 31 and 44 nM, respectively. Ensartinib exhibited comparable inhibitory effects on cell migration as crizotinib and tepotinib in both cell types. In vivo, ensartinib suppressed the growth of Hs746T cells. Ensartinib also potently inhibited the viability of PDOs. Overall, Ensartinib exhibited substantial antitumor effects against METex14 mutant NSCLCs in preclinical and clinical trials, with relatively low peripheral edema rates." @default.
- W4328103238 created "2023-03-22" @default.
- W4328103238 creator A5001969147 @default.
- W4328103238 creator A5007462622 @default.
- W4328103238 creator A5010806376 @default.
- W4328103238 creator A5014390459 @default.
- W4328103238 creator A5024156060 @default.
- W4328103238 creator A5025095617 @default.
- W4328103238 creator A5028773984 @default.
- W4328103238 creator A5035976373 @default.
- W4328103238 creator A5037057883 @default.
- W4328103238 creator A5057881041 @default.
- W4328103238 creator A5073309453 @default.
- W4328103238 creator A5073511034 @default.
- W4328103238 creator A5076320154 @default.
- W4328103238 creator A5079377765 @default.
- W4328103238 creator A5089013677 @default.
- W4328103238 date "2023-05-01" @default.
- W4328103238 modified "2023-09-26" @default.
- W4328103238 title "Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer" @default.
- W4328103238 cites W2032817710 @default.
- W4328103238 cites W2094337993 @default.
- W4328103238 cites W2102377211 @default.
- W4328103238 cites W2126372889 @default.
- W4328103238 cites W2137488285 @default.
- W4328103238 cites W2159426719 @default.
- W4328103238 cites W2160212814 @default.
- W4328103238 cites W2230948985 @default.
- W4328103238 cites W2272081149 @default.
- W4328103238 cites W2327451947 @default.
- W4328103238 cites W2466657922 @default.
- W4328103238 cites W2587620487 @default.
- W4328103238 cites W2595593937 @default.
- W4328103238 cites W2604488177 @default.
- W4328103238 cites W2613355447 @default.
- W4328103238 cites W2738959174 @default.
- W4328103238 cites W2739232261 @default.
- W4328103238 cites W2791185794 @default.
- W4328103238 cites W2954589648 @default.
- W4328103238 cites W2980903799 @default.
- W4328103238 cites W2981693848 @default.
- W4328103238 cites W3000668520 @default.
- W4328103238 cites W3011041856 @default.
- W4328103238 cites W3031018272 @default.
- W4328103238 cites W3082015854 @default.
- W4328103238 cites W3175096644 @default.
- W4328103238 cites W3179682885 @default.
- W4328103238 cites W3196750844 @default.
- W4328103238 doi "https://doi.org/10.1016/j.canlet.2023.216140" @default.
- W4328103238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36948240" @default.
- W4328103238 hasPublicationYear "2023" @default.
- W4328103238 type Work @default.
- W4328103238 citedByCount "0" @default.
- W4328103238 crossrefType "journal-article" @default.
- W4328103238 hasAuthorship W4328103238A5001969147 @default.
- W4328103238 hasAuthorship W4328103238A5007462622 @default.
- W4328103238 hasAuthorship W4328103238A5010806376 @default.
- W4328103238 hasAuthorship W4328103238A5014390459 @default.
- W4328103238 hasAuthorship W4328103238A5024156060 @default.
- W4328103238 hasAuthorship W4328103238A5025095617 @default.
- W4328103238 hasAuthorship W4328103238A5028773984 @default.
- W4328103238 hasAuthorship W4328103238A5035976373 @default.
- W4328103238 hasAuthorship W4328103238A5037057883 @default.
- W4328103238 hasAuthorship W4328103238A5057881041 @default.
- W4328103238 hasAuthorship W4328103238A5073309453 @default.
- W4328103238 hasAuthorship W4328103238A5073511034 @default.
- W4328103238 hasAuthorship W4328103238A5076320154 @default.
- W4328103238 hasAuthorship W4328103238A5079377765 @default.
- W4328103238 hasAuthorship W4328103238A5089013677 @default.
- W4328103238 hasBestOaLocation W43281032381 @default.
- W4328103238 hasConcept C121608353 @default.
- W4328103238 hasConcept C126322002 @default.
- W4328103238 hasConcept C143998085 @default.
- W4328103238 hasConcept C197934379 @default.
- W4328103238 hasConcept C203092338 @default.
- W4328103238 hasConcept C2776232967 @default.
- W4328103238 hasConcept C2776256026 @default.
- W4328103238 hasConcept C2778570526 @default.
- W4328103238 hasConcept C2779422266 @default.
- W4328103238 hasConcept C2908647359 @default.
- W4328103238 hasConcept C502942594 @default.
- W4328103238 hasConcept C535046627 @default.
- W4328103238 hasConcept C71924100 @default.
- W4328103238 hasConcept C72563966 @default.
- W4328103238 hasConcept C98274493 @default.
- W4328103238 hasConcept C99454951 @default.
- W4328103238 hasConceptScore W4328103238C121608353 @default.
- W4328103238 hasConceptScore W4328103238C126322002 @default.
- W4328103238 hasConceptScore W4328103238C143998085 @default.
- W4328103238 hasConceptScore W4328103238C197934379 @default.
- W4328103238 hasConceptScore W4328103238C203092338 @default.
- W4328103238 hasConceptScore W4328103238C2776232967 @default.
- W4328103238 hasConceptScore W4328103238C2776256026 @default.
- W4328103238 hasConceptScore W4328103238C2778570526 @default.
- W4328103238 hasConceptScore W4328103238C2779422266 @default.
- W4328103238 hasConceptScore W4328103238C2908647359 @default.
- W4328103238 hasConceptScore W4328103238C502942594 @default.
- W4328103238 hasConceptScore W4328103238C535046627 @default.